Warsaw Orthopedic, Inc. v. Nuvasive, Inc.

824 F.3d 1344, 118 U.S.P.Q. 2d (BNA) 1792, 2016 U.S. App. LEXIS 10092, 2016 WL 3124704

• Court: Court of Appeals for the Federal Circuit
• Decided: June 3, 2016
• Docket: 2013-1576, 2013-1577
• Status: Published

Opinions

Concurring opinion filed by Circuit Judge REYNA.

DYK, Circuit Judge.

This case returns to this court on vaca-tur and remand from the Supreme Court, “for further consideration in light of Commil USA LLC v. Cisco Systems, Inc., — U.S. -, [135 S.Ct. 1920, 191 L.Ed.2d 883 (2015) ].” Medtronic Sofamor Danek USA, Inc. v. NuVasive, Inc., — U.S. -, 136 S.Ct. 893, 193 L.Ed.2d 785 (2016) (Mem.). On remand, we reaffirm the district court’s judgment with respect to U.S. Patent No. 7,470,236 (“the ’236 patent”) and reinstate our earlier judgment in other respects.

BACKGROUND

The vacated decision, Warsaw Orthopedic, Inc. v. NuVasive, Inc., 778 F.3d 1365 (Fed. Cir. 2015), began as a patent infringement suit by Warsaw Orthopedic, Inc. and a related company, Medtronic Sofamor Danek USA, Inc., (“MSD”)¹ against NuVasive, Inc. (“NuVasive”). Nu-Vasive counterclaimed for infringement of its patent, U.S. Patent No. 7,470,236 (“the ’236 patent”). Only our' decision with respect to the ’236 patent is affected by the Supreme Court’s remand. That aspect of our decision affirmed a jury verdict of infringement, holding that the asserted claims of NuVasive’s-’236 patent were directly infringed by users of MSD’s “NIM-Eelipse” device and that MSD induced this infringement. Id. at 1369,1373,1379.

Our opinion issued on March 2, 2015. The Supreme Court decided Commit shortly thereafter, on May 26, 2015. 135 S.Ct. at 1920. MSD subsequently petitioned for certiorari in this case, requesting that the Court grant certiorari, vacate, and remand (“GVR”) on the basis that our court did not correctly apply the test for induced infringement under 35 U.S.C. § 271(b) articulated, in Commit and the Court’s earlier decision in Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 131 S.Ct. 2060, 179 L.Ed.2d 1167 (2011). MSD contended that while the jury had been properly instructed as to the standard of induced infringement set out in Commil, NuVasive had failed to prove that MSD had the requisite knowledge to induce infringement. MSD did not raise any issue concerning a belief in patent invalidity, the Supreme Court in Commil having held that a belief in patent invalidity is not a defense to inducement. 135 S.Ct. at 1928. The Supreme Court granted certiorari and issued its GVR order on January 19, 2016.

We recalled our mandate and reopened the case on March 3, 2016. We requested supplemental briefing from MSD and Nu-Vasive on “the question of what action this court should take on remand from the Supreme Court ‘for further consideration in light of Commil....”’ March 2, 2016, Order, ECF No. 93. We now consider what action is appropriate in this case in light of the Supreme Court’s remand.

DISCUSSION

I

The only question here is whether there was substantial evidence for the jury to conclude that MSD induced infringement of NuVasive’s ’236 patent. The Supreme Court’s decision in Commil reaffirmed and clarified the Court’s earlier decision in Global-Tech on the standard for inducement under § 271(b) but did not change the law. See Commil, 135 S.Ct. at 1927-28. Commil, like Global-Tech, held that proof of induced infringement requires not “only knowledge of the patent” but also “proof the defendant knew the [induced] acts were infringing.” Id. at 1926, 1928. Commil, in reaffirming Global-Tech, also necessarily reaffirmed that willful blindness can satisfy the knowledge requirement for active inducement under § 271(b) (and for contributory infringement under § 271(c)), even in the absence of actual knowledge. Global-Tech, 131 S.Ct. at 2070.

Global-Tech also held that knowledge of infringement can be inferred from circumstantial evidence. Id. at 2071-72. In this respect, Global-Tech affirmed the Supreme Court’s and our court’s earlier precedents, which held that the “requisite intent to induce infringement may be inferred from all of the circumstances.” Broadcom Corp. v. Qualcomm Inc., 543 F.3d 683, 699 (Fed. Cir. 2008) (quoting Water Techs. Corp. v. Calco, Ltd., 850 F.2d 660, 669 (Fed. Cir. 1988)); see also MGM Studios Inc. v. Grokster, Ltd., 545 U.S. 913, 936, 939-940, 125 S.Ct. 2764, 162 L.Ed.2d 781 (2005) (applying the inducement standard of patent law in a copyright context and holding that circumstantial evidence demonstrated an “unmistakable” “unlawful objective” to induce infringement); Lucent Techs., Inc., v. Gateway, Inc., 580 F.3d 1301, 1322 (Fed. Cir. 2009) (“A plaintiff may ... prove the intent element through circumstantial evidence, just as with direct infringement....”); Fuji Photo Film Co., Ltd. v. Jazz Photo Corp., 394 F.3d 1368, 1377 (Fed. Cir. 2005) (“A patentee may prove intent through circumstantial evidence.”); Water Techs., 850 F.2d at 660 (“While proof of intent is necessary, direct evidence is not required; rather, circumstantial evidence may suffice.”).

II

The ’236 patent is directed to a method for detecting the presence of and measuring distance to a nerve during surgery. Warsaw, 778 F.3d at 1372. The patented method requires sending a series of electrical pulses that gradually increase in strength until á pulse reaches sufficient strength to elicit a nerve response. Id. Proximity to the nearest nerve is proportional to the strength of the pulse that elicited the response. Id. NuVasive asserted claims 1, 5, and 9 of the ’236 patent, of which claim 1 is representative. Claim 1 is reproduced in full in our earlier opinion, id. but only one limitation, the “stopping” step, is relevant to this case on remand. The “stopping” step of claim 1 is step (c), which requires “increasing the intensity level of said stimulus signal until said predetermined neuro-muscular response is elicited by said stimulus pulse and stopping the emission of said stimulus signal immediately after said predetermined neu-ro-muscular response is detected.” ’236 patent col. 17 11. 56-60. In the earlier appeal we held that substantial evidence supported the jury’s finding of direct infringement of claim 1 of the ’236 patent by surgeons using MSD’s device, the “NIM-Eclipse.” Id. at 1373. That determination is not reopened by the Supreme Court’s remand.

The district court concluded that the “stopping” step — specifically, the claim term, “stopping the emission of said stimulus signal immediately after said predetermined neuro-muscular response is detected” — did not need to be construed and consequently did not provide the jury with any construction (although the court did construe the embedded term “stimulus signal,” as discussed below). In determining whether the NIM-Eclipse met the “stopping” step, the jury was required to apply the “plain meaning to a person of ordinary skill in the art at the time of the invention.” J.A. 206.

There is no dispute that the jury was correctly instructed as to the standard for induced infringement under Global-Tech (and Commil). The jury was instructed that it was NuVasive’s burden to prove that “the alleged infringer knew or was willfully blind to the fact that the induced acts constituted patent infringement of at least one patent claim,” in addition to the other elements of induced infringement. J.A. 213. MSD does not dispute that the jury was correctly instructed as to the relevant claim limitations of the ’236 patent and as to NuVasive’s burden to prove infringement by a preponderance of the evidence.

Thus, the question before us now is a limited one: whether the jury was presented with substantial evidence that MSD knew (or was willfully blind to the fact) that it was instructing doctors to infringe the ’236 patent. MSD acknowledges that its “challenge is to the sufficiency of the evidence that it indirectly infringed.” Appellants’ Supp. Br. at 14. In the earlier appeal we did not address that question explicitly, stating only that “[tjhere was evidence that MSD was aware of the patent prior to the litigation and that MSD specifically taught doctors to use the product during the surgical procedures in an infringing manner.” Warsaw, 778 F.3d at 1373. We now address the question. We must sustain the jury’s verdict if there was substantial evidence before the jury to support an inference that MSD knew (or was willfully blind to the fact) that doctors’ use of its device infringed the ’236 patent.

Ill

MSD argues that no reasonable jury could have inferred from the evidence before it that MSD had knowledge of (or was willfully blind to) its customers’ infringement of the ’236 patent. However, here we conclude that there was substantial evidence that MSD’s infringement position was objectively unreasonable and that the jury, based on this evidence, could reasonably have concluded that MSD had knowledge (or was willfully blind to the fact) that it was infringing.

The central premise of MSD’s non-infringement position is that it reasonably construed narrowly the “stopping” limitation of the claims of the ’236 patent to require a complete termination of emission of any and all electrical pulses. “Stopping the emission of the signal thus means the electrode — i.e., the device — must stop emitting any signal, which indisputably is not what occurs when a NIM-Eclipse device detects a nerve.” Appellants’ Supp. Br. at 10. After the NIM-Eclipse emits a stimulus signal that detects a nerve, it continues emitting electrical pulses at a lower energy rather than stopping emission of all electrical signals. MSD argues that this property of the NIM-Eclipse led MSD to believe that the device did not infringe the ’236 patent.

But on its face, claim 1 of the ’236 patent says something different. Claim 1 requires “stopping the emission of said stimulus signal immediately after said predetermined neuro-muscular response is detected.” ’236 patent col. 17 11. 58-60. That is, claim 1 requires stopping a particular kind of signal, “said stimulus signal,” and does not require stopping any and all electrical signals emitted by the device.

At the district court, both parties agreed that “a stimulus signal” is a signal able to elicit a neuromuscular response (i.e., a nerve response). MSD asked the district court to construe “stimulus signal” to mean “a signal that can stimulate.” J.A. 1871 (MSD’s Responsive Claim Construction Brief). MSD expressly explained that, under its construction, a stimulus signal is one capable of stimulating a nerve. “Per Medtronic’s construction, ‘a signal that can stimulate,’ a stimulus signal is able to elicit a response to detect nerve proximity, but does not cease being a ‘stimulus signal’ merely because it is not currently eliciting a response_” J.A. 1871 (emphasis added). NuVasive requested a similar construction, “an electrical signal for eliciting a neuromuscular response,” which the district court adopted. J.A. 21-22 (District Court’s Markman Order). MSD’s Responsive Claim Construction Brief emphasized its agreement that a “stimulus signal” is a signal capable of eliciting a nerve response. “In NuVasive’s words, ‘not every signal is an electrical signal ... and not every stimulation can cause a neuromuscu-lar response.’ Medtronic agrees, and its construction of this term does not contradict these assertions.” J.A. 1871 (quoting NuVasive’s Opening Claim Construction Brief). The jury was properly instructed to construe “stimulus signal” according to the district court’s construction to mean “an electrical signal for eliciting a neuromuscu-lar response.” J.A. 208.

The language of claim 1 clearly requires stopping the emission not of any or all stimulus signals but of one particular stimulus signal: “said stimulus signal,” the signal that triggered a response from the nerve being probed. As MSD itself put it, “[t]he claim language ‘said’ means that the ‘stimulus signal’ and ‘predetermined neu-romuscular response’ elements modified by ‘said’ are the same signal and response referenced earlier in the claim.” J.A. 1872 (MSD’s Responsive Claim Construction Brief). In MSD’s words, under “the very clear language of claim 1,” “the steps contemplate emission of one signal to elicit one neuro-muscular response, with that same signal stopping upon the detection of that response.” Id.

MSD’s claim is that the “stopping” limitation requires total cessation of any and all electrical stimulus pulses emitted by the nerve-monitoring device. It insists that “[shopping the emission of the signal thus means the electrode — i.e., the device— must stop emitting any signal.” Appellants’ Supp. Br. at 10. This theory is clearly inconsistent with the construction of “said stimulus signal” that MSD itself propounded.

MSD also argues that the prosecution history of the ’236 patent, which was before the jury, supports MSD’s interpretation of the “stopping” step and its theory that the jury could not have found the knowledge (or willful blindness) necessary for induced infringement. The prosecution history here does not help MSD. The prosecution history shows that NuVasive amended the claims of the application that became the ’236 patent to overcome the examiner’s obviousness rejection over a prior art reference, U.S. Patent No. 5,284,-153 (“Raymond T53”), by adding the “stopping” limitation. Raymond ’153 describes a method of probing a nerve at a constant level of stimulation, thereby eliciting multiple neuromuscular responses from the same nerve. Raymond T53 col. 3 11. 29-35. NuVasive argued that its method, with the “stopping” step, provided increased safety compared to Raymond T53 because NuVasive’s method avoided over-stimulation of the nerve:

Claim 15 [which became claim 1 of the ’236 patent] has also been amended to reflect that the emission of the stimulus signal is immediately stopped after the predetermined neuro-muscular response is detected. This is a safety mechanism designed to remove the stimulation of the spinal nerve during the processing time required to communicate the intensity level to a user.... This avoids the unnecessary stimulation found, for example, in the Raymond T53 reference. ... [Raymond ’153] does not stop the stimulation altogether, as found in claim 15, and thus subjects the nerve to unnecessary stimulation that may result in irritation and/or damage over time.

J.A. 2895 (NuVasive’s Amendment and Remarks of October 12, 2007). Contrary to MSD’s argument, the prosecution history thus demonstrates that “stopping” refers to stoppage of the stimulus signal capable of eliciting a neuromuscular response, not necessarily stoppage of any and all electrical stimulus.

In short, there is no support in the language of claim 1 of the ’236 patent or its prosecution history to support MSD’s position that infringement of the “stopping” limitation requires complete termination of any and all electrical stimulus pulses from a nerve-probing device. Claim 1 recites “stopping the emission of said stimulus signal,” not stopping the emission of all electrical signals.

In any event, MSD’s effort at this late stage amounts to a request for a revised claim construction that it never sought. That is improper, as we previously ruled in our earlier opinion. Warsaw, 778 F.3d at 1373 (citing Hewlett-Packard Co. v. Mustek Sys., Inc., 340 F.3d 1314, 1321 (Fed. Cir. 2003)). Moreover, claim construction is, of course, ultimately a question of law that must be left to the court, not the jury. Teva Pharm. USA, Inc. v. Sandoz, Inc., — U.S. -, 135 S.Ct. 831, 837, — L.Ed.2d - (2015). We have previously held that it is improper for juries to hear conflicting expert testimony on the correctness of a claim construction, given the risk of confusion. CytoLogix Corp. v. Ventana Med. Sys., Inc., 424 F.3d 1168, 1172 (Fed. Cir. 2005); see also Sundance, Inc. v. DeMonte Fabricating Ltd., 550 F.3d 1356, 1364 n. 6 (Fed. Cir. 2009).

IV

Turning to the issue that is properly before us, undisputed evidence before the jury showed that, immediately after nerve stimulation, the NIM-Eclipse reduced the strength of the electrical stimulus pulses it emitted to a level that was not capable of stimulating the nerve that had provided the neuromuscular response. In other words, the “said stimulus signal” emitted by the NIM-Eclipse was stopped immediately after the neuromuscular response was detected.

MSD does not dispute that whenever the NIM-Eclipse device emits a “stimulus signal” at the threshold intensity sufficient to elicit a nerve response, the next pulse is emitted at lower intensity. As such, the record shows that “said stimulus signal” as construed by the court — the electrical signal for eliciting a neuromuscular response, capable of stimulating the nerve being probed — “stops” immediately after the response is detected, just as the claims of the ’236 patent require. This evidence was before the jury, and the jury could reasonably have concluded that MSD had the requisite knowledge of infringement.

Given the strength of the evidence Nu-Vasive presented, a reasonable jury could have concluded that MSD must have known that its NIM-Eclipse device “stopped” emitting “said stimulus signal” immediately after that signal elicited a neuromuscular response. MSD’s knowledge of the ’236 patent is undisputed. As such, under these circumstances, a reasonable jury could have concluded that MSD’s non-infringement position was objectively unreasonable and that MSD must have known that NIM-Eclipse meets the limitations of the claims of the ’236 patent. A reasonable jury could therefore have inferred that MSD must have known, or was willfully blind to the fact, that doctors using the device infringe those claims.²

Conolusion

We again affirm the district court’s judgment of January 26, 2012, with respect to direct and indirect infringement of the ’236 patent. In view of that judgment, we also affirm the district court’s June 10, 2013, award of an ongoing royalty to be paid by MSD to NuVasive for post-verdict sales of the NIM-Eclipse device. We reinstate our earlier judgment with respect to NuVasive’s infringement of MSD’s patents, which was unaffected by the Supreme Court’s GVR order. Warsaw, 778 F.3d at 1379.

AFFIRMED-IN-PART, VACATED-IN-PART, AND REMANDED-IN-PART

Costs

Costs to NuVasive.

1 . For simplicity, we refer to Warsaw Orthopedic, Inc. and Medtronic Sofamor Danek USA, Inc. collectively as "MSD."

2 . The concurrence expresses concern that the majority opinion could be read to suggest “that any time a defendant’s products are found to directly infringe, the plaintiff has sufficiently established the defendant’s intent to induce infringement." Concurrence at 4. To be clear, we do not suggest that inducement liability is that broad. To show the intent to induce infringement, it is sufficient that the plaintiff establish that a defendant's asserted belief in non-infringement was unreasonable.